RPG Life Sciences Intrinsic Value
RPG Life Sciences (RPGLIFE) median intrinsic value is ₹1117.34 from 9 valuation models (range ₹670–₹1591), vs current price ₹2232.60 — -50.0% downside (Trading Above Calculated Value), margin of safety -99.8%. Also explore RPG Life Sciences share price performance to track price trends across different timeframes.
RPGLIFE Valuation Methods Summary — DCF, Graham Number & P/E
RPG Life Sciences intrinsic value across 9 models vs current price ₹2232.60 — upside/downside and value range per method. Browse RPGLIFE income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1591.04 | ₹1272.83 - ₹1909.25 | -28.7% | EPS: ₹72.32, Sector P/E: 22x |
| Book Value Method | asset | ₹930.77 | ₹837.69 - ₹1023.85 | -58.3% | Book Value/Share: ₹465.38, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1169.23 | ₹1052.31 - ₹1286.15 | -47.6% | Revenue/Share: ₹584.62, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1415.38 | ₹1273.84 - ₹1556.92 | -36.6% | EBITDA: ₹184.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹893.04 | ₹714.43 - ₹1071.65 | -60.0% | CF Growth: 7.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹669.78 | ₹602.80 - ₹736.76 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1117.34 | ₹1005.61 - ₹1229.07 | -50.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1292.31 | ₹1163.08 - ₹1421.54 | -42.1% | ROE: 19.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹870.21 | ₹783.19 - ₹957.23 | -61.0% | EPS: ₹72.32, BVPS: ₹465.38 |
RPGLIFE Intrinsic Value vs Market Price — All Valuation Models
RPG Life Sciences fair value range ₹670–₹1591 vs current market price ₹2232.60 across 9 valuation models. For current market price and key ratios, visit RPGLIFE stock price BSE.
RPGLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
RPG Life Sciences median intrinsic value ₹1117.34, current price ₹2232.60 — Trading Above Calculated Value by 50.0%, margin of safety -99.8%.
What is the intrinsic value of RPGLIFE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of RPG Life Sciences (RPGLIFE) is ₹1117.34 (median value). With the current market price of ₹2232.60, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹669.78 to ₹1591.04, indicating ₹669.78 - ₹1591.04.
Is RPGLIFE undervalued or overvalued?
Based on our multi-method analysis, RPG Life Sciences (RPGLIFE) appears to be trading above calculated value by approximately 50.0%.
RPGLIFE Financial Health — Key Ratios vs Industry Benchmarks
RPG Life Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 19.44 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.96x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
RPGLIFE Cash Flow Quality — Operating & Free Cash Flow
RPG Life Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹78 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹94 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹91 Cr | ₹38 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹65 Cr | ₹48 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹58 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |